Answers are grounded in this paper and cite their sources.
Demonstrates a novel method to synthesize beraprost sodium in a precise diastereomeric ratio, suggesting improved treatment strategies for PAH.
(±)-Beraprost sodium is an oral prostacyclin drug used to treat pulmonary arterial hypertension (PAH). It exists as a mixture of two C-4 diastereomers in a ratio of approximately 1:1, which presents significant challenges for process development. Herein, we report a novel and convergent total synthesis of (±)-beraprost sodium that enables precise control over the C-4 stereochemistry. This synthesis features key transformations including the Mitsunobu reaction, ring-closing metathesis, intramolecular Heck reaction, and cross-electrophile coupling, providing an efficient route to the target compound. Furthermore, systematic investigation into Horner-Wadsworth-Emmons olefination and ketone reduction has yielded a robust method for achieving the desired 1:1 diastereomeric ratio at C-4 from the asymmetric skeleton.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: